| Cancer |
Research |
| Breast Cancer |
A phase 1B study to evaluate safety anf clinical activity of pembrolozumab (MK-3475) in combination with chemotherapy as neoadjuvant treatment for trible negative breast cancer |
| Breast Cancer |
A randomized phase III study comparing trastuzumap, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer |
| Breast Cancer |
A Phase II randomized, douple-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breats cancr subjects with bone metastases treated with hormonl treatment background therapy |
| Breast Cancer |
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who have received two prior Anti-HER2 therapies and require systemic treatment |
| Esophagus Cancer |
A phase III randomized open-label study of single agent pembrolizumab vs physicians' choise of single agent docetaxel, paclitaxel or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first line standard therapy |
| Gastric Cancer |
Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients metastatic gastrointestinal tract adenocarcinoma: a randomized phase II study |
| Gastrointestinal Cancer |
Open-label, single-arm, phase II study of bevacizumab in combination with alternating XELIRI and XELOX as first-line treatment of patients with metastatic colorectal cancer |
| GIST |
A randomized phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumor (GIST) |
| GIST |
Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomized phase III study |
| Lymphoma |
A phase 1/2 study of combination of pixantrone, etoposide, bendamustine and in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T- cell phenotype- The PREBEN study |
| Lymphoma |
Brentuxumab vedotin or B-CAP in treatment of older patients with newly diagnosed classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II- trial |
| Lymphoma |
A phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL)- CHRonos-4 |
| Lymphoma |
Alemtuzumab and CHOP in T-cell lymphoma (The ACT-1 trial): A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomas. |
| Lymphoma |
Open-label, uncontrolled phase II trial of intravenous PI3K inhibitor BAY-80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin´s lymphomas |
| Lymphoma |
A comparative, randomoized, parallel-group, multi-centre phase IIIb study to investigate the efficacy of sc rituximab vs iv ritiximab both in combination with CHOP (R-CHOP) in previously untreated patients with CD20 positive diffuse large B-cell lymphoma |
| Lymphoma |
Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk Diffuse Large B-Cell Lymphoma (NLG-LBC05) |
| Lymphoma |
A multicenter phase III, open-label, randomized study in previously untreated patients with advanced indolent Non-hodgkin's lymfphoma evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with rituximab plus chemotherapy followed by GA101 or rituximamb maintenance therapy in responders |
| Lymphoma |
A randomized, douple-blind, placebo-controlled phase 3 -study of the bruton´s tyrosine kinase (bkt) inhibitor, pci-32765 (ibrutinib), in combination with rituximab, cyclophosphamide, doxorubisin, vincristine and prednisone (r-chop) in subjects with newly diagnosed non- germinal subtype of diffuse large b-cell lymphoma |
| Melanoma |
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trail on the EORTC Melanoma Group |
| Melanoma |
A phase 3, randomized, double-blind study of adjuvant immunotherapy with nivolumb verus ipilimumab after complete resection of stage IIIB/C or stage IV melanoma in subjects who are at high risk for recurrence |
| Melanoma |
The Melanoma Group Trial: TOL+ vemurafenib followed by interferon + vemurafenib maintenance (BRAF- positive patents) or TOL followed by interferon maintenance (BRAF-negative patients) |
| Pancreatic Cancer |
A phase 3, multicenter, open-label, randomized study of nab-paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma "apact" |
| Prostate Cancer |
Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (DUALIDES) |
| Rectum Cancer |
A phase III study pf pembrolizumab (MK-3475-177 MCRC) vs chemotherapy in microsatelliet instability-high (MSH-H) or mismatch repair deficient (dMMR) stage IV colorectal carsinoma |
| Rectum Cancer |
Full dose monotherapy S-1 (followed by irinotecan) compared to reduced dose combination therapy (S-1/pxaliplatin followed by S-1/irinotecan) as initilal therapy for older patients with metastatic colorectal cancer |
| Renal Cancer |
A phase 3, randomized, open-label study of nivolumab combined with ibilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma |
| Renal Cancer |
CA209-214 A phase 3, randomized, open-label study of nivolumab combined with ibilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma |
| Solid Tumor |
A phase 1/2 study of safety and efficacy of ulocuplumab combined with nivolumab in subjects with advanced or metastatic solid tumors |
| Solid Tumor |
An open label, multicohort, phase II study of MPDL3280A in advanced solid tumors |
| Solid Tumor |
An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplification |
| Solid Tumor |
Safety and pharmacokinetics of ODM-207 in patienst with selected advanced tumors; an open-label, non-randomosed, uncontrolled, multicentre, first-in-human study with cohort expansion |
| Solid Tumor |
CA209-032 A Phase 1/2 open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors |
| Solid Tumor |
Safety and tolerability of single and repeated doses of ODM-203: an opel-label, non-randomized, uncontrolled, dose escalation, multicentre, first-in-human study in subjects with advanced solid tumors |
| Thyroid Cancer |
Reduction in radioiodine treatments in low risk papillary thyroid cancer |